Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.51 |
| ▸ | FASN | P49327 | 1/20 | 0.47 |
| ▸ | USP5 | P45974 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.44 |
| ▸ | GCGR | P47871 | 3/20 | 0.43 |
| ▸ | MMP2 | P08253 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.41 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8502960 | 0.91 | CYP1A2 (0.47) | FFAR1LMNACYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL11757895 | 0.85 | SRD5A2 (0.61) | FFAR1LMNACYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL11758065 | 0.85 | LMNA (0.54) | FFAR1LMNACYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL6418614 | 0.84 | FASN (0.44) | LMNASMN1; SMN2FASNSRD5A2GCGR | |
| SCHEMBL6418612 | 0.84 | FASN (0.44) | LMNASMN1; SMN2FASNSRD5A2GCGR | |
| SCHEMBL11759367 | 0.83 | KMT2A (0.53) | FFAR1LMNACYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL7862901 | 0.83 | FFAR1 (0.51) | FFAR1LMNACYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL6224543 | 0.82 | SRD5A2 (0.64) | LMNARAB9ASMN1; SMN2FASNSRD5A2 | |
| SCHEMBL7441533 | 0.81 | CYP1A2 (0.60) | FFAR1LMNACYP1A2RAB9ASMN1; SMN2 | |
| SCHEMBL11762828 | 0.80 | RAB9A (0.51) | FFAR1LMNACYP1A2RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6307089-B2 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-10-23 | — | — | US | disclosed |
| US-6239288-B1 | RHEUMATIC DISEASES | WARNER-LAMBERT COMPANY | 2001-05-29 | — | — | US | disclosed |
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | WARNER-LAMBERT COMPANY | 2001-04-26 | — | — | US | disclosed |
| EP-0927156-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1999-07-07 | — | — | EP | disclosed |
| WO-1998009940-A1 | BIPHENYL BUTYRIC ACIDS AND THEIR DERIVATIVES AS INHIBITORS OF MATRIX METALLOPROTEINASES | WARNER-LAMBERT COMPANY (US) | 1998-03-12 | — | — | WO | disclosed |
| US-4021479-A | ANTIPHLOGISTICS AND ANTIPROLIFERATIVES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010000513-A1 | Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases | MMP26, MMP1, MMP9 | FFAR1 515/4885LMNA 1839/4885CYP1A2 1694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.